Nilotinib
- Generic Name
- Nilotinib
- Brand Names
- Tasigna, Nilotinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H22F3N7O
- CAS Number
- 641571-10-0
- Unique Ingredient Identifier
- F41401512X
- Background
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), anoth...
- Indication
For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myeloid Leukemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Refractory Gastrointestinal stromal tumor
- Associated Therapies
- -
MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04559555
Nilotinib, for Patients With CML-CP or CML-AP
- Conditions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04518644
MAP to Provide Access to Nilotinib, for Patients With HES
- Conditions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04498871
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2023-02-27
- Target Recruit Count
- 20
- Registration Number
- NCT04205903
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Masaryk University
- Target Recruit Count
- 150
- Registration Number
- NCT04147533
- Locations
- 🇨🇿
University Hospital Kralovske Vinohrady, Praha, Czechia
🇨🇿Insitute of Hematology and Blood Transfusion, Praha, Czechia
🇨🇿University Hospital Plzen, Plzen, Czechia
Nilotinib for First-line Newly Diagnosed CML-CP Patients
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Shenzhen Second People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03942094
- Locations
- 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
Effect of Nilotinib in Cerebellar Ataxia Patients
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT03932669
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT03885830
- Locations
- 🇺🇸
UNC Hospital, Chapel Hill, North Carolina, United States
De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination
- Conditions
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT03874858
- Locations
- 🇮🇹
Novartis Investigative Site, Novara, Italy
Molecular Profiling of Advanced Soft-tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 603
- Registration Number
- NCT03784014
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷IUCT Oncopôle, Toulouse, France
🇫🇷Institut de Cancérologie de Montpellier, Montpellier, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.